Redefining Access To Medical Care
Founded on the principle 'Medtech for many', Tata MD aims to bring medical care closer to the patient and their physicians.
We started by developing and manufacturing breakthrough innovations in compact molecular and immuno diagnostic platforms and a holistic condition management approach that makes delivery of care convenient and accessible.
At Tata Medical and Diagnostics, our aspiration is to build a world-class diagnostics and medical solutions organisation with a culture of open innovation, global network and reach, backed by world-class, responsible corporate practices and underlined by the values of the Tata Group. We aim to build a new ecosystem by engaging with the medical care and diagnostics community, including its practitioners, innovators, organisations, policymakers, and patients, with focus, integrity and compassion.
Shape Evolution
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Patient Centric Solution
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Technology Capabilities
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Connected Care
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
What We Do
We are currently focused on diagnostics and safety service solutions for COVID-19 and building a complete portfolio of innovative diagnostic solutions across application areas.
What We Do
We are currently focused on diagnostics and safety service solutions for COVID-19 and building a complete portfolio of innovative diagnostic solutions across application areas.
Our research-driven strategy is in the course of rolling out products and services that will revolutionise healthcare with affordable and reliable diagnostics for other diseases.
TataMD check
Tata MD CHECK test is the new standard in COVID-19 diagnosis, based on FELUDA CRISPR-Cas9 genomic technology. it is designed as an AI powered complete testing platform to provide fast and high quality results, and simple testing experience. TataMD CHECK has transformed COVID-19 diagnosis enabling healthcare providers and diagnostic centres to fast-track testing services.
TataMD Secure
Tata MD SECURE offers a comprehensive set of healthcare and safety services to help curb the spread of COVID-19. A host of services combining technology and healthcare has been designed to ensure safety at workplaces, educational institutes and events. Services include setting up safety guidelines, assessing safety, consulting and emergency healthcare, testing, contract tracing, bio-bubble security, among others.
Our Associations
Bringing together the best and the most respectable custodians of healthcare provision and medical research in India.
Institute of Genomics and Integrative Biology is a premier scientific research institute, that’s part of The Council of Scientific and Industrial Research(CSIR). IGIB’s research include subjects of national importance like genomics, molecular medicine, bioinformatics and proteomics.
What Healthcare Leaders Say About Us
Prof K. VijayRaghavan
Principal Scientific Adviser, Government of India
“I am very pleased to see that the Council for Scientific and Industrial Research through its laboratories, the IGIB, and other centres have developed a rapid COVID testing kit that is efficient and can quickly be deployed widely. It is such partnerships and innovation which can result in rapid testing, contact tracing, and isolation so that the lives and livelihood of people can go on. It’s great to see that the Tata sons have taken up this initiative and combined it with an extraordinary logistical and analytical backend to help spread this innovation all over India and the world. Kudos to everyone involved; the Tata Sons and the CSIR.”
Prof. Balram Bhargava
Padmashri Secretary to the GOI, Health Research, MOHFW Director General, Indian Council of Medical Research (ICMR)
“When the pandemic hit India in early March, we had a very limited number of laboratories, and RT-PCR was the gold standard. I am delighted that, Tata MD CHECK is going to be a path-breaking CRISPR based technology, which will be a shot in the arm of India’s COVID testing strategy and will also contribute immensely towards India’s 5T strategy towards the COVID pandemic – Testing, Tracking, Tracing, Treating, and the use of Technology. I wish this technology all the success.”
Dr. Shekar C. Mande
Director General, Council of Scientific and Industrial Research (CSIR)
“I am very pleased that Tata MD CHECK based on the FELUDA platform has been launched. This is a great example of academia along with industry partnership and is a terrific illustration of CSIR and Tata’s partnership. Tata MD CHECK is a fast diagnostic tool, is cost-effective, and very easy to use. We are extremely proud of this innovation and thrilled to have further strengthened our partnership with Tata with this project. I wish everyone involved in this project and Tata MD a very successfully run – looking forward to many more collaborations in the coming time.”
Dr. Anurag Agarwal
Director, Institute of Genomics and Integrative Biology (IGIB)
“From the time when FELUDA, the lab technology of CSIR-IGIB has become Tata MD CHECK, a world-class diagnostic product– it has been an extremely enriching journey. We had a very promising technology based on CRISPR for which the 2020 Nobel-prize in Chemistry was awarded for genome editing. We have applied this technology towards diagnosing the presence of the SARS-CoV-2 virus which causes COVID-19. This initiative will provide access to testing for people in far-flung areas where expensive machines may not be available. Our partners, Tata Medical and Diagnostics that have supported us in every step of the entire process.”
Prof. R. K. Kotnala
Chairman, NABL
“Our Atmanirbhar program has been supported by the Tata Group by developing a novel CRISPR Cas-9 test kit, based on FELUDA for COVID-19 testing in India. The CRISPR Cas-9 test is the pride of India – having been innovated and developed in partnership by Tata Medical and Diagnostics and CSIR-IGIB in India. The test has been approved by the ICMR that confirms it to be a big breakthrough in COVID-19 testing for the masses. The test is simple and delivers results very quickly – with accuracy on par with q-PCR tests.”
Dr. Souvik Maiti
Senior Principal Scientist, CSIR – IGIB
“CRISPR Cas9 technology allows anybody to change the genetic material DNA/RNA or can be used to correct genetic disorders. While working to correct single sickle cell anaemia disease we came out with a particular Cas9 protein and noticed that this CRISPR Cas9 protein has a unique ability to distinguish a different signature in nucleic acid. With the onset of the pandemic, we realized that we could fine-tune this technology to detect the SARS-CoV-2 virus and thus FELUDA was born. We were extremely proud to receive an all-clear from the ICMR as well as the DCGI, India’s highest medical regulatory bodies for commercial launch of this COVID-19 diagnostic tool as Tata MD CHECK . I am extremely happy with the partnership between IGIB and Tata MD. I look forward to many more collaborative projects.”
Dr. Debojyoti Chakraborty
Senior Scientist, CSIR – IGIB
“The FELUDA technology uses a regular PCR machine which is extremely cost-effective– this means that testing can be ramped up almost 20 times at places using a regular PCR machine. The test uses a combination of CRISPR technology and paper strip chemistry. We are very excited and hopeful that this innovation will help take more testing to the ground – to places where q-RT-PCR is unable to reach, and places where COVID testing must be ramped up.”
Dr. Sachin Honguntikar
Head - Anderson Clinical Genetics
“We can proudly say that we are the first lab in the country that has been approved for CRISPR Cas-9 based technology for COVID testing. Tata MD CHECK is very user-friendly compared to the currently available RT-PCR method and technology. Results are uncomplicated to analyze, produced within two hours, and do not require highly skilled lab technicians or lab equipment to conduct – making it extremely cost-effective. Further to this Tata MD CHECK’s ability to be conducted in a remote facility makes testing possible in villages and far-flung areas, directly making testing accessible to more people.”
Dr. Ritu Bisht,
Consultant Pathologist, Dr. Ahuja's Pathology and Imaging Center
“I would like to thank the Tata MD team for taking this opportunity to work with a brand-new technique called CRISPR FELUDA. This technique is as good as the RT-PCR that is currently in use for COVID-19 testing. The pipetting automation technique is extremely beneficial, this technique does away with an extremely prone human error process i.e., manual pipetting. Further to this, the automation of reporting where results are directly uploaded to the ICMR portal helped streamline the entire testing process. Tata MD’s CRISPR FELUDA technique along with the mobile van is very beneficial for large-events that require large-volume testing in a day.”
Dr. S K Jha
CMO, Haridwar, Uttarakhand
“By identifying areas where there was a high volume of people – we, along with the help of Tata Medical and Diagnostics strategically set up testing centres. Using Tata MD CHECK, tests were conducted at these strategic high traffic areas in and around Hairdwar. With its quick turnaround time, results were delivered made available, and we were further able to detect and control the spread of the COVID-19”.
Dr. Prashant Khadke,
COO Pensive Health, Spectrum Laboratory
“A simple and beautiful technology that fully automates the wet lab testing process; this along with Tata’s AI-driven data interpretation helps save valuable time, especially when handling a large number of samples. With sensitivity and specificity on par with the golden standard real-time PCR technology. We have personally experienced testing over 700 samples in under 12 hours. A truly amazing technology combined with stellar support from Tata team has made COVID testing seamless, accurate, and quick.”
Dr. Kavitha M.P,
Lead Consultant Microbiologist, Aster DM Healthcare
“Tata MD CHECK based on cutting edge CRISPR technology is playing a pivotal role in COVID-19 testing. The technology is fast, providing a testing turnaround time of under 4 hours. We are extremely proud that Tata in partnership with CSIR-IGIB has developed this indigenous testing capability. Soon this technology can further serve as a diagnostic tool in other fields such as oncology and multiple other infectious parameters.”
In The News
Anderson Diagnostics launches Tata MD CHECK
on 24/03/2021
Tata Medical and Diagnostics (Tata MD), the new healthcare venture from the house of Tata, announced today that it has entered into a wide-ranging clinical collaboration with Chennai-based Anderson Diagnostics & Labs (ADL), to standardize the indigenously-developed Tata MD CHECK in a bid to slow down the rate of new infections. The collaboration with clinical experts of ADL has helped ensure that the "Made-in-India" Tata MD CHECK diagnostic kit can be scaled rapidly with ADL having already successfully conducted over 10,000 COVID tests using this new, DGCA approved ICMR guidelines, novel diagnostic solution based on Feluda CRISPR Platform. `Having tested and validated more than 10000 samples, we feel this technology is on par with the best in the world and futuristic as well. Moreover, Tata MD CHECK's ability to perform using inexpensive lab equipment like standard thermocyclers will be a boost for small labs in tier 11/111 towns and villages to start COVID testing locally" said Dr AnandKri shnamoorthy, Managing Director, Anderson Diagnostics. "Working with the exceptional team at Anderson Diagnostics has demonstrated the impact that a new technology-based product like Tata MD CHECK can have on strengthening our COVID testing capacity and access to testing in remote areas. Tata's clinical collaboration with Anderson Diagnostics will only drive advances in the diagnostic space of COVID-19 as the pandemic continues" said Girish Krishnainurthy, MD & CEO, Tata Medical and Diagnostics.
Tata firm launches 75-minute test for COVID-19
Business Standard 10 November
Tata Medical and Diagnostics (Tata MD) on Monday launched new diagnostic testing for COVID-19 — claiming it to be more efficient and simpler than the existing ones — with the ability to scale up test on a large scale across the country. The company's test Tata MD CHECK has been developed in partnership with CSIR-IGIB (Council of Scientific and Industrial Research-Institute of Genomics and Integrative Biology),It has been approved by Indian Council of Medical Research and Drug Controller General of India (DCGI) and will be available through diagnostic centers and hospitals across India shortly. the company said. To make the test available across India, the company is talking to hospital chains, diagnostic players and laboratories for partnership and it is ready with a monthly production capacity of a million units a month to start with at its Chennai factory. We have come to a solution which provides end-to-end testing experience. We make the testing much more efficient and reliable and scalable, that creates more access and availability. Moreover, this whole thing is developed in India," Tata Medical and Diagnostics CEO Girish Krishnamurthy said. In June. CSIR-IGIB came up with a breakthrough to detect the COVID-19 virus by gene sensing through innovation on a platform called FELUDA using the latest CRISPR technology, which is generally used for gene editing, he added. We partnered with IGIB lab and then worked very closely with them. Getting the whole science from the lab into a product, today we are ready for a commercial launch of the product within about 100 days. We worked very hard toga this system," he added. Tata MD CHECK is a paper strip-based test with an image-based visual result readout. It requires standard laboratory equipment and small batches of tests can be conducted. Moreover, it has a fast reaction time of 45-50 minutes in the laboratory and the total testing time from RNA-extracted samples in the lab to result is 75 minutes only, the company said. Also, it can "provide high quality, quick results using standard equipment and minimally trained staff allow for rapid adoption The company is ready with 1 million tests/month capacity and scale with potential to reach remote locations of India". Krishnamurthy said this product does not require any complicated machine, unlike the current testing models, thereby makeing it easier to set it up in a lab. Besides, it also takes lesser steps as compared to the current models and hence making it less complicated and reducing inefficiencies. A major advantage is that testing can be done in any denomination of sample, while the current models of testing require the test to be run in batches of a certain number of samples and bring out the results in a batch.
Tata group launches `Feluda' test kits:
Times of India 10th Nov 2020
Tate Medical and Diagnostics (Tata MD) announced the commercial launch of Tata MD CHECK. a diagnostic gene-based testing wit kit for COVID 19. It is powered by 'Feluda', a CRISPR Cas-9 technology developed by leading research institute. CSIR-IGIB. The company claims a quicker, simpler, and cheaper process as against the other technology. RT-PCR (Reverse transcription polymerase chain reaction) — considered the gold standard method for COVID 19 testing.
Tata Group Rolls Out 'Faster COVID Tests'
The Economic Times_Kolkata_
Tata Group launched a COVID test kit on Monday that it says will process results more easily and faster than the RT-PC12 method.
Tata MD & ADL partner to transform COVID testing
The Pioneer Hyderabad 24th March
Tata Medical and I Diagnostics (Tata MD) has collaborated with city-based Anderson Diagnostics and Labs to standardise the indigenously developed diagnostic kit Tata MD CHECK in a bid to slow down the rate of new COVID-19 infections. This is part of a wide ranging clinical collaboration between the two companies. The 'Made-in-India' Tata MD CHECK diagnostic kit can be scaled rapidly with Anderson Diagnostics Labs having already successfully conducted over 10,000 COVID-19 tests, using the DGCA approved Indian Council of Medical Research guidelines, novel diagnostic solution based on Feluda CRISPR Platform, a company statement said. "Tata's CRISPR-based platform is a rock-solid COVID test that can be programmed for early detection and treatment of a number of other diseases and conditions as well," Anderson Diagnostics and Labs Director Dr Srinivasaraman said.
Tata MD, Anderson Diagnostic Labs partner for COVID testing
Afternoon_Coimbatore MARCH 23 2020
Tata Medical and Diagnostics (Tata MD), the new healthcare venture from the house of Tata, announced today that it has entered into a wide-ranging clinical collaboration with Chennai-based Anderson Diagnostics &Labs (ADL), to standardize the indigenously - developed Tata MD CHECK in a bid to slow down the rate of new infections. The collaboration with clinical experts of ADL has helped ensure that the "Made-in-India" Tata MD CHECK diagnostic kit can be scaled rapidly with ADL having already successfully conducted over 10,000 COVID tests using this new, DOCA approved ICMR guidelines, novel diagnostic solution based on Feluda CRISPR Platform. "Tata's CRISPR-based platform is a rock-solid COVID test that can be programmed for early detection and treatment of a number of other diseases and conditions as well. The indigenously developed TataMD CHECK based on Feluda offers a clear, quicker, and more accessible alternative to RT-PCR, the current mainstay of COVID tests. Our clinical partnership with Tata MD will help support the transformation of COVID testing to arrest the emergence of a second wave in India and around the world." said Dr Srinivasaraman, Director, Anderson Diagnostics and Labs.
Tata Medical launches Feluda COVID test kits under brand Check
Mint_10th Nov 2020
Tata Medical and Diagnostics Limited on Mon- 0. day launched its COVID-I9 test under the brand Check. The paper-based test is powered by the Feluda technology it developed along with Council of Scientific and Industrial Research's constituent lab. Institute of Genomics and Integrative Biology (CSIR-IGIB).
Tata MD and Anderson Diagnostic Labs partner to transform COVID testing through Tata MD CHECK
The Economic Times_Kolkata_
Tata Group launched a COVID test kit on Monday that it says will process results more easily and faster than the RT-PC12 method.
Tata MD CHECK to make COVID-19 detection simpler, quicker and more accessible
Mumbai, November 9, 2020
Mumbai, November 9, 2020 Tata Medical and Diagnostics Ltd. (Tata MD), the healthcare venture from Tata Group, has announced the commercial launch of Tata MD CHECK, a novel diagnostic testing for COVID-19. Tata MD CHECK is powered by FELUDA, a CRISPR Cas-9 technology that was developed in India by CSIR- IGIB for COVID testing. It is the world’s first CRISPR Cas-9 based diagnostic tool to be launched globally. Within a short span of 100 days from licensing the technology to its commercial launch, intense collaboration between the CSIR-IGIB team, other reputed scientific research bodies and the Tata MD R&D team helped develop, a compelling end-to-end diagnostic solution that will set the new standard in testing. It has been developed with secure supply-chains backed with a layer of digital services. Tata MD CHECK has been approved by Indian Council of Medical Research and Drug Controller General of India (DCGI) and will be available through diagnostic centers and hospitals across India shortly. Tata MD CHECK is a lab test and uses CRISPR-Cas9 Technology. The process of collecting patient samples, RNA extraction and amplification etc remain same but uses simple, less expensiveequipment and produces quicker results due to a more agileprocess and AI-based automated result detection. The key advantages of Tata MD Check testing are: Simplicity: It is a paper strip-based test with an image-based visual result read out. It requires standard laboratory equipment and small batches of tests can be conducted. Quick Results: Fast reaction time of 45-50 minutes in the laboratory and the total testing time from RNA-extracted sample in the lab to result is 75 minutes only. Scalability: Ability to provide high quality, quick results using standard equipment and minimally trained staff allows for rapid adoption and scale with potential to reach remote locations of the country. Digital backbone: Continuous quality control using sensors and AI-based result reporting tool will help patients and authorities with the evidence of test, traceability of the sample and results accessible anywhere on cloud storage. A New Paradigm for the Diagnostic Industry Tata MD CHECK offers laboratories, hospitals and other healthcare providers to fast-track COVID diagnosis services to more people. It allows diagnostic centres to offer COVID-19 testing solutions at more locations due to two reasons: Lower capital costs since the testing can be done on standard available equipment instead of expensive qPCR machines. Hence new testing centres that are closer to the consumers in Tier II & III cities as also semi-rural areas can be set up Technology-backed faster test process: Quicker Results and Higher Throughput of testing volumes gives greater agility for labs as there are no minimum batch sizes Commenting on the launch, Girish Krishnamurthy, CEO, Tata Medical and Diagnostics said, “Tata MD aims to be a trusted, long term partner and help shape the evolution of healthcare industry towards building a more inclusive and integrated patient-centric model. With Tata MD CHECK, we are committed to significantly enhance the testing experience of the consumers as well as work with laboratories and hospitals to ensure wider availability and easier access to testing. The pandemic has encouraged us to reflect on the healthcare sector and our role in bridging the many gaps that exists. Our collaboration with R&D institutions will continue to be a critical part of our strategy to introduce new diagnostic technologies like CRISPR, and develop R&D-led healthcare solutions for consumers for COVID and other infectious diseases.” Tata MD Check test kits will be manufactured at a quality-controlled production facility near Chennai, Tamil Nadu. The production plant presently has a capacity of producing 1 million kits in a month. Tata MD is also typing up with leading diagnostic chains, hospitals, healthcare centres to enhance the adoption of these tests apart from partnering with Government agencies. About Tata Medical and Diagnostics Ltd (Tata MD) Tata Medical and Diagnostics Ltd (Tata MD), the wholly-owned healthcare venture from the Tata Group, aims to provide leading-edge, patient-centric solutions to make healthcare access more reliable for consumers. Tata MD’s products and solutions will span different facets of a fast-evolving healthcare economy including the launch CRISPR-based innovative diagnostics, state-of-the-art medical devices as well as integrated ‘connected care’ solutions for rural and urban consumers.Launched during the 2020 pandemic, Tata MD has developed and launched Tata MD CHECK, the world’s first commercially available CRISPR Cas-9 based COVID-19 test, powered by FELUDA from CSIR-IGIB, a leading Indian biosciences research institute.